EsoBiotec is pioneering a transformative approach to cancer treatment through the development of in vivo engineered CAR-T cells. This innovative technology empowers the body to produce its own cancer therapies, significantly enhancing the patient experience by streamlining treatment administration and accelerating access to care. The approach not only reduces costs but also mitigates the risk of host versus graft rejection, thereby simplifying hospital processes and improving overall treatment outcomes for cancer patients.

The company is led by a team of seasoned experts with extensive experience in cell and gene therapies, particularly in the context of CAR-T cell therapies. Their commitment to advancing cancer immunotherapy is reflected in their focus on building a diverse team of researchers skilled in various fields, including protein engineering, immunology, and virology. This multidisciplinary approach positions EsoBiotec at the forefront of biotech innovation, with the potential to redefine standards in cancer treatment and significantly improve the lives of patients.

Belgium

EsoBiotec is a biotechnology company developing an in vivo engineering platform to produce cancer fighting cells inside the patient's body.

EsoBiotec

Company Details